Trial Profile
A Real-world study to compare the safety and efficacy of Adalimumab, Etanercept and Ustekinumab in patients with moderate-severe psoriasis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Aug 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Ustekinumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 28 Aug 2018 New trial record
- 01 Aug 2018 Results published in the Journal of Dermatological Treatment